
Reza Sari Motlagh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4224853/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Intravesical Therapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence. European Urology Focus, 2022, 8, 447-456.	1.6	3
2	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. BJU International, 2022, 129, 182-193.	1.3	16
3	Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. European Urology Focus, 2022, 8, 761-768.	1.6	10
4	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. Cancer Immunology, Immunotherapy, 2022, 71, 85-95.	2.0	6
5	Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis. European Urology Focus, 2022, 8, 752-760.	1.6	8
6	Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile. Minerva Urology and Nephrology, 2022, 74, .	1.3	2
7	The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials. European Urology Oncology, 2022, 5, 138-145.	2.6	6
8	Systemic therapies for metastatic hormoneâ€sensitive prostate cancer: network metaâ€analysis. BJU International, 2022, 129, 423-433.	1.3	37
9	Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. European Urology Focus, 2022, 8, 1072-1089.	1.6	14
10	Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis. World Journal of Urology, 2022, 40, 907-914.	1.2	19
11	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. Molecular Carcinogenesis, 2022, 61, 5-18.	1.3	6
12	Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy Sources. Journal of Endourology, 2022, 36, 535-547.	1.1	11
13	Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 95.e1-95.e6.	0.9	20
14	Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. World Journal of Urology, 2022, 40, 747-754.	1.2	4
15	Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2022, 27, 59-71.	1.0	19
16	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3091-3102.	1.2	2
17	Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. Critical Reviews in Oncology/Hematology, 2022, 169, 103570.	2.0	11
18	Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Minerva Urology and Nephrology, 2022, 74, .	1.3	8

REZA SARI MOTLAGH

#	Article	IF	CITATIONS
19	The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. European Urology Focus, 2022, 8, 972-979.	1.6	3
20	<i>En Bloc</i> Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology. Journal of Urology, 2022, 207, 754-768.	0.2	26
21	Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. European Urology Oncology, 2022, 5, 120-124.	2.6	6
22	Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis. Scandinavian Journal of Urology, 2022, 56, 85-93.	0.6	3
23	Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis. Arab Journal of Urology Arab Association of Urology, 2022, 20, 71-80.	0.7	2
24	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. Annals of Surgical Oncology, 2022, 29, 5307-5316.	0.7	6
25	Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis. European Urology Focus, 2022, 8, 1687-1695.	1.6	10
26	Prognostic impact of insulinâ€like growth factorâ€l and its binding proteins, insulinâ€like growth factorâ€l binding proteinâ€2 and â€3, on adverse histopathological features and survival outcomes after radical cystectomy. International Journal of Urology, 2022, , .	0.5	3
27	Comparative Outcomes of Primary Versus Recurrent High-risk Non–muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study. European Urology Open Science, 2022, 39, 14-21.	0.2	7
28	The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis. International Immunopharmacology, 2022, 108, 108720.	1.7	13
29	The placebo and nocebo effects in functional urology. Nature Reviews Urology, 2022, 19, 171-189.	1.9	5
30	Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis. Journal of Robotic Surgery, 2022, 16, 1233-1247.	1.0	6
31	Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis. Prostate Cancer and Prostatic Diseases, 2022, 25, 187-198.	2.0	7
32	Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy, 2022, 14, 709-725.	1.0	10
33	Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review. Translational Cancer Research, 2022, 11, 908-917.	0.4	2
34	ASO Visual Abstract: Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. Annals of Surgical Oncology, 2022, , 1.	0.7	0
35	Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 315-330.	0.8	15
36	Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma. European Urology Focus, 2022, 8, 1683-1686.	1.6	4

Reza Sari Motlagh

#	Article	IF	CITATIONS
37	Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. World Journal of Urology, 2021, 39, 1757-1768.	1.2	20
38	Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis. European Urology Focus, 2021, 7, 1143-1156.	1.6	6
39	The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and metaâ€analysis. BJU International, 2021, 127, 143-152.	1.3	5
40	Primary Ta high grade bladder tumors: Determination of the risk of progression. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 132.e7-132.e11.	0.8	9
41	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 235.e5-235.e14.	0.8	8
42	Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review. Arab Journal of Urology Arab Association of Urology, 2021, 19, 59-66.	0.7	12
43	Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. OncoTargets and Therapy, 2021, Volume 14, 315-324.	1.0	5
44	Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. World Journal of Urology, 2021, 39, 3345-3352.	1.2	18
45	The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. Journal of Urology, 2021, 205, 60-67.	0.2	36
46	Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. Turkish Journal of Urology, 2021, 47, S33-S44.	1.3	1
47	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Translational Andrology and Urology, 2021, 10, 609-619.	0.6	5
48	Penile Rehabilitation Strategy after Nerve Sparing Radical Prostatectomy: A Systematic Review and Network Meta-Analysis of Randomized Trials. Journal of Urology, 2021, 205, 1018-1030.	0.2	27
49	Benefit of Adjuvant Chemotherapy After Radical Cystectomy for Treatment of Urothelial Carcinoma of the Bladder in the Elderly –An International Multicenter Study. Bladder Cancer, 2021, 7, 173-185.	0.2	Ο
50	Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review. World Journal of Urology, 2021, 39, 4085-4099.	1.2	9
51	Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of nonâ€muscleâ€invasive bladder cancer: a systematic review and network metaâ€analysis of randomized trials. BJU International, 2021, 128, 280-289.	1.3	17
52	Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy. World Journal of Urology, 2021, 39, 3771-3779.	1.2	10
53	Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer. Annals of Surgical Oncology, 2021, 28, 9179-9187.	0.7	3
54	Intracorporeal versus extracorporeal urinary diversion in robot-assisted radical cystectomy: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2021, 26, 1587-1599.	1.0	16

REZA SARI MOTLAGH

#	Article	IF	CITATIONS
55	Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy. Journal of Urology, 2021, 206, 1122-1131.	0.2	5
56	Impact of systemic Immune–inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 785.e19-785.e27.	0.8	14
57	Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. World Journal of Urology, 2021, 39, 4355-4361.	1.2	18
58	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. International Journal of Clinical Oncology, 2021, 26, 1729-1735.	1.0	3
59	Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 806-815.	0.8	7
60	First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. European Journal of Cancer, 2021, 151, 35-48.	1.3	24
61	Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 764-773.	0.8	14
62	Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. Immunotherapy, 2021, 13, 917-929.	1.0	1
63	Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 471-479.	0.8	7
64	Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials. Seminars in Oncology, 2021, 48, 181-192.	0.8	2
65	Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy. Journal of Personalized Medicine, 2021, 11, 1231.	1.1	5
66	Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. Minerva Urology and Nephrology, 2021, 73, 610-615.	1.3	6
67	Association of statins use and mortality outcomes in prostate cancer patients who received androgen deprivation therapy: a systematic review and meta-analysis. Central European Journal of Urology, 2021, 74, 484-490.	0.2	2
68	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Minerva Urology and Nephrology, 2021, , .	1.3	8
69	Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 936.e7-936.e14.	0.8	3
70	Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy. Current Opinion in Urology, 2020, Publish Ahead of Print, 701-710.	0.9	6
71	Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2020, 25, 1881-1891.	1.0	8
72	Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. International Journal of Clinical Oncology, 2020, 25, 1892-1900.	1.0	45

5

REZA SARI MOTLAGH

#	Article	IF	CITATIONS
73	Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC). World Journal of Urology, 2020, 39, 1961-1968.	1.2	10
74	Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2020, 25, 1459-1474.	1.0	25
75	Management of de-novo urothelial carcinoma in transplanted patients. Current Opinion in Urology, 2020, 30, 467-474.	0.9	7
76	Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2020, 23, 539-548.	2.0	27
77	Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2020, 25, 1037-1054.	1.0	31
78	Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 774-782.	0.8	26
79	The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 204, 909-917.	0.2	21
80	Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?. Current Opinion in Urology, 2020, 30, 584-593.	0.9	5